Researchers at the University of Surrey are creating immune digital twins, virtual models of individual immune systems, to advance personalised medicine and deliver tailored treatments.
Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, explains why drug-candidate ABX464 has the potential to address the urgent need for new, safe short- and long-term effective drugs to treat Inflammatory Bowel Diseases.
Aarthi JanakiRaman, Research Director, Chemicals and Advanced Materials at TechVision, Frost & Sullivan, explains how glycoscience offers opportunities galore in healthcare.
In Bangladesh, children are fighting a difficult battle to survive antibiotic resistance - now, mid-pandemic, pneumonia is becoming untreatable via normal drugs.
Rachel Thrasher, Research Fellow at the Global Development Policy Center in Boston, explains how the new US stance could change the TRIPS waiver debate.
The CureVac mRNA vaccine is currently in final stages of clinical trials - but it is expected to perform like Pfizer and Moderna, with the bonus of surviving at ordinary refrigeration temperatures.
